C. Sternberg

1.4k total citations
67 papers, 1.1k citations indexed

About

C. Sternberg is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, C. Sternberg has authored 67 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 23 papers in Surgery and 22 papers in Oncology. Recurrent topics in C. Sternberg's work include Bladder and Urothelial Cancer Treatments (20 papers), Renal cell carcinoma treatment (17 papers) and Prostate Cancer Treatment and Research (17 papers). C. Sternberg is often cited by papers focused on Bladder and Urothelial Cancer Treatments (20 papers), Renal cell carcinoma treatment (17 papers) and Prostate Cancer Treatment and Research (17 papers). C. Sternberg collaborates with scholars based in Italy, United States and France. C. Sternberg's co-authors include Howard I. Scher, Fabio Calabrò, Janice Gabrilove, Ann A. Jakubowski, John Grous, Alan Yagoda, Daniel P. Petrylak, Katie Fain, Bayard Clarkson and Herbert F. Oettgen and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

C. Sternberg

66 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Sternberg Italy 16 606 397 228 225 210 67 1.1k
Giuseppe Fornarini Italy 22 562 0.9× 597 1.5× 166 0.7× 305 1.4× 245 1.2× 125 1.3k
Loı̈c Mourey France 16 882 1.5× 565 1.4× 277 1.2× 271 1.2× 206 1.0× 107 1.5k
M. Neil Reaume Canada 18 642 1.1× 461 1.2× 218 1.0× 234 1.0× 302 1.4× 66 1.1k
Alec Goldenberg United States 18 228 0.4× 432 1.1× 188 0.8× 139 0.6× 429 2.0× 41 1.3k
Carole Hélissey France 14 558 0.9× 527 1.3× 197 0.9× 126 0.6× 163 0.8× 81 1.1k
Rita Lionetto Italy 20 320 0.5× 962 2.4× 295 1.3× 295 1.3× 133 0.6× 53 1.4k
Mark Shapiro United States 21 537 0.9× 471 1.2× 59 0.3× 183 0.8× 157 0.7× 49 1.4k
Alessandra Ravaioli Italy 19 533 0.9× 913 2.3× 209 0.9× 161 0.7× 210 1.0× 107 1.3k
Ana C. Xavier United States 13 1.1k 1.8× 1.1k 2.7× 333 1.5× 123 0.5× 518 2.5× 51 1.8k
Catharina Wenzel Austria 22 376 0.6× 979 2.5× 403 1.8× 126 0.6× 221 1.1× 48 1.4k

Countries citing papers authored by C. Sternberg

Since Specialization
Citations

This map shows the geographic impact of C. Sternberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Sternberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Sternberg more than expected).

Fields of papers citing papers by C. Sternberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Sternberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Sternberg. The network helps show where C. Sternberg may publish in the future.

Co-authorship network of co-authors of C. Sternberg

This figure shows the co-authorship network connecting the top 25 collaborators of C. Sternberg. A scholar is included among the top collaborators of C. Sternberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Sternberg. C. Sternberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fizazi, Karim, Matthew Ryan Smith, Muhammad Hussain, et al.. (2022). 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study. Annals of Oncology. 33. S1162–S1162. 4 indexed citations
2.
Bamias, Aristotelis, Kimon Tzannis, Lauren C. Harshman, et al.. (2017). Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC). Annals of Oncology. 28. v305–v305. 1 indexed citations
3.
Sternberg, C., Giuseppe Procopio, Ettore Seregni, Roberto Salvioni, & R. Valdagni. (2015). Radium-223 alpha emitter agent in safety study in mCRPC popUlation for long-teRm evaluation (REASSURE). Annals of Oncology. 26. vi64–vi64. 1 indexed citations
4.
Graff, Julie N., G. Baciarello, Andrew J. Armstrong, et al.. (2015). Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Annals of Oncology. 27(2). 286–294. 86 indexed citations
5.
Halabi, Susan, Chenyu Lin, Eric J. Small, et al.. (2013). Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. JNCI Journal of the National Cancer Institute. 105(22). 1729–1737. 114 indexed citations
6.
Milowsky, Mathew I., et al.. (2011). A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3.. Journal of Clinical Oncology. 29(15_suppl). TPS186–TPS186. 7 indexed citations
7.
Xu, Chun‐Fang, Howard Ball, Nan Bing, et al.. (2011). Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma.. Journal of Clinical Oncology. 29(7_suppl). 303–303. 11 indexed citations
8.
Tran, Hang, Amelia Rodríguez Martín, Amado J. Zurita, et al.. (2011). Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).. Journal of Clinical Oncology. 29(7_suppl). 334–334. 8 indexed citations
9.
Sternberg, C., Robert E. Hawkins, Cezary Szczylik, et al.. (2011). A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): Updated safety results.. Journal of Clinical Oncology. 29(7_suppl). 313–313. 11 indexed citations
10.
Cerbone, Linda, Rita Van Ginderdeuren, Joost van den Oord, et al.. (2009). 9326 Clinical presentation, pathological features and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease. European Journal of Cancer Supplements. 7(2). 585–585. 1 indexed citations
11.
Joniau, Steven, Lodovico Balducci, M. Bolla, et al.. (2008). SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY). European Urology Supplements. 7(3). 300. 1 indexed citations
12.
Sternberg, C.. (2008). Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Annals of Oncology. 19. vii91–vii95. 26 indexed citations
13.
Nathan, Faith E., C. Sternberg, Oliver Sartor, et al.. (2005). Satraplatin: A new treatment option for patients with hormone refractory prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4802–4802. 4 indexed citations
14.
Sternberg, C.. (2002). Current perspectives in muscle invasive bladder cancer. European Journal of Cancer. 38(4). 460–467. 21 indexed citations
15.
Sternberg, C.. (1999). A critical review of the management of bladder cancer. Critical Reviews in Oncology/Hematology. 31(3). 193–207. 8 indexed citations
16.
Sternberg, C., et al.. (1997). S. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the EORTC. Annals of Oncology. 8. 696–706. 3 indexed citations
17.
Sternberg, C., John Jasek, Marcia S. Driscoll, et al.. (1996). A Model for the Delivery of Care for HIV-Positive Clients. AIDS Patient Care and STDs. 10(4). 240–245. 5 indexed citations
18.
Fosså, S.D., et al.. (1996). Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. British Journal of Cancer. 74(10). 1655–1659. 36 indexed citations
19.
Sternberg, C., Maria Arena, Vito Pansadoro, et al.. (1992). Recombinant tumor necrosis factor for superficial bladder tumors. Annals of Oncology. 3(9). 741–745. 9 indexed citations
20.
Gabrilove, Janice, Ann A. Jakubowski, Katie Fain, et al.. (1988). Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.. Journal of Clinical Investigation. 82(4). 1454–1461. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Fornarini Breakdown of academic impact, for papers by Loı̈c Mourey Breakdown of academic impact, for papers by M. Neil Reaume Breakdown of academic impact, for papers by Alec Goldenberg Breakdown of academic impact, for papers by Carole Hélissey Breakdown of academic impact, for papers by Rita Lionetto Breakdown of academic impact, for papers by Mark Shapiro Breakdown of academic impact, for papers by Alessandra Ravaioli Breakdown of academic impact, for papers by Ana C. Xavier Breakdown of academic impact, for papers by Catharina Wenzel
Rankless by CCL
2026